Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820505 | 0.93 | KMT2A (0.53) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| SCHEMBL11964593 | 0.90 | KMT2A (0.50) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| SCHEMBL2821901 | 0.88 | KMT2A (0.55) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| SCHEMBL2819366 | 0.87 | KMT2A (0.54) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| SCHEMBL2820975 | 0.87 | KMT2A (0.54) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| SCHEMBL2819586 | 0.87 | KMT2A (0.54) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| SCHEMBL2821332 | 0.87 | KMT2A (0.75) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| SCHEMBL2820403 | 0.87 | KMT2A (0.54) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| SCHEMBL2819559 | 0.87 | USP2 (0.60) | PKMTSHRKDM4EKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2821822 | 0.86 | USP2 (0.59) | PKMTSHRKDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849469-B1 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2010-10-27 | — | — | EP | claimed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | claimed |
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | CCR3, CCR1, CCR2 | PKM 4352/4885TSHR 2167/4885KDM4E 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.